The addition of agonists to the intracellular TLRs, TLR7, TLR8 and TLR9, prior to infection in PBMCs has been shown to exhibit anti-HIV activity by inducing high levels of the type-1 interferons and interferon-stimulated genes [40]. The gene discussed is TLR9; the disease is infection.